Viridian Therapeutics
VRDN
73 hedge funds and large institutions have $461M invested in Viridian Therapeutics in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 3 closing their positions.
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
33% more funds holding
Funds holding: 55 → 73 (+18)
0% more capital invested
Capital invested by funds: $460M → $461M (+$1.46M)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
10.8% less ownership
Funds ownership: 107.09% → 96.29% (-11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.4M |
| 2 |
Millennium Management
New York
|
+$9.86M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$5.8M |
| 4 |
CC
Commodore Capital
New York
|
+$1.99M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$29.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.58M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.32M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.2M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$2.6M |
VRDN Hedge Fund Activity: Q1 2022 in Review
73 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2022, worth a combined $461M — up 0.32% from $460M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VRDN positions and 3 closed out — a net gain of 18 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $13.4M. The largest seller was Frazier Management, exiting entirely with an estimated $29.8M sold.
- 73 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2022, up from 55 in Q4 2021.
- Funds reported $461M of Viridian Therapeutics stock for Q1 2022, up 0.32% quarter-over-quarter.
- 21 funds opened new Viridian Therapeutics positions in Q1 2022 and 3 closed out, a net change of +18 holders.
- The largest Viridian Therapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $13.4M added.
- The largest Viridian Therapeutics seller in Q1 2022 was Frazier Management, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2022.